

Intelligent Ultrasound Group plc
(the "Group" or the "Company")

Notice of results
Analyst and investor briefing

Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company, specialising in artificial intelligence (AI) software and simulation, announces it will issue its interim results for the six months ended 30 June 2024 on Wednesday, 14 August 2024.

A briefing for analysts will be held via video call on 14 August 2024 at 09:30am BST. To register, please contact intelligentultrasound@tbcardew.com

The Company will host a live presentation for investors given by CEO Stuart Gall and CFO Helen Jones via the Investor Meet Company platform on Wednesday, 14 August 2024 at 11:00am BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 13 Aug 2024, 09:00am BST, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet the Company via: <https://www.investormeetcompany.com/intelligent-ultrasound-group-plc/register-investor>

Investors who already follow Intelligent Ultrasound on the Investor Meet Company platform will automatically be invited.

For further information, please contact:

Intelligent Ultrasound Group plc

Stuart Gall, CEO
Helen Jones, CFO

www.intelligentultrasound.com

Tel: +44 (0)29 2075 6534

Cavendish Capital Markets Limited
(Nominated advisor and broker)

Giles Balleny (Corporate Finance)
Nigel Birks (ECM)
Dale Bellis (Sales)

Tel: +44 (0)20 7397 8900

TB Cardew - PR Advisors

Ed Orlebar
Allison Connolly
Emma Pascoe-Watson
Jessica Pilling

Intelligentultrasound@tbcardew.com

Tel: +44 (0)7738 724630
Tel: +44 (0)7587 453955
Tel: +44 (0)7774 620415
Tel: +44 (0)7918 584573

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to clinic' ultrasound companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market ('classroom') and artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market ('clinic'). Based in Cardiff in the UK and Atlanta in the US, the Group has two revenue streams:

Simulation

Real-time hi-fidelity ultrasound education and training through simulation. Our main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eye Point of Care and Emergency Medicine training simulator with Covid-19 module and the new BabyWorks Neonate and Paediatric training simulator. To date over 1,700 simulators have been sold to over 800 medical institutions around the world.

Clinical AI software

Deep learning-based algorithms to make ultrasound machines smarter and more accessible using our proprietary ScanNav ultrasound image analysis technology. Current products on the market utilising this technology are GE HealthCare's SonoLyst software that is incorporated in their Voluson Expert and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies ultrasound-guided needling by providing the user with real-time AI-based anatomy highlighting for a range of medical procedures; and NeedleTrainer that teaches real-time ultrasound-guided needling and incorporates ScanNav Anatomy PNB.

www.intelligentultrasound.com

NOTE: ScanNav Anatomy PNB is CE approved and cleared for sale in the US by the FDA but is not available for sale in any other territory requiring government approval for this type of product.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORMZGFNLGMDZM